Welcome to our dedicated page for BioCardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCardia, Inc. SEC filings document a clinical-stage biotechnology and medical-device business focused on cell therapies and related delivery technologies for cardiovascular and pulmonary disease. Recent Form 8-K reports cover Regulation FD disclosures and other events involving CardiAMP clinical data, FDA and PMDA regulatory interactions, the Helix transendocardial delivery catheter, and patent protection for Heart3D Fusion Imaging software.
The company’s filings also record annual operating results, research and development activity, liquidity-related financial disclosures, and Nasdaq continued-listing compliance matters. These documents frame BCDA’s public-company record around product-development programs, regulatory pathways, intellectual property, capital and listing status, risk disclosures, and corporate reporting obligations.
BioCardia, Inc. reported second quarter 2026 results highlighting supportive regulatory feedback and a narrower loss. Japan’s PMDA indicated it supports a regulatory submission for CardiAMP Cell Therapy for ischemic heart failure, the FDA indicated the CardiAMP HF II trial may be sufficient for U.S. approval, and the FDA also said DeNovo approval of the Helix transendocardial delivery catheter is possible. The company is preparing a PMDA submission for the fourth quarter, continues enrolling the CardiAMP HF II trial, and is awaiting FDA minutes on the Helix DeNovo pre-submission.
For the quarter ended June 30, 2026, net loss was $1.6 million compared with $2.0 million a year earlier, with net loss per share of $0.13 versus $0.40. Research and development expenses were $0.9 million and selling, general and administrative expenses were $0.7 million. For the first six months of 2026, net loss was $3.9 million versus $4.8 million. As of June 30, 2026, cash and cash equivalents were $4.1 million and total stockholders’ equity was $2.7 million.
BioCardia, Inc. reported a smaller net loss while strengthening its balance sheet but continues to face severe funding risk. For the six months ended June 30, 2026, net loss was $3.9 million compared with $4.8 million a year earlier, as research and development expenses declined to $2.1 million from $2.9 million with the CardiAMP Heart Failure Trial winding down. Selling, general and administrative costs stayed roughly flat at $1.8 million.
Cash and cash equivalents increased to $4.1 million from $2.5 million at year-end 2025, driven by $5.3 million in gross proceeds from at-the-market stock sales in the first half of 2026. Stockholders’ equity improved to $2.7 million. Management nonetheless states there is substantial doubt about the company’s ability to continue as a going concern beyond January 2027 without additional capital. Operationally, BioCardia highlights regulatory momentum: Japan’s PMDA feedback supports a CardiAMP submission in ischemic heart failure, and FDA minutes indicate the ongoing CardiAMP Heart Failure II trial may support Premarket Approval. Early CardiAMP chronic myocardial ischemia data and progress on the CardiALLO and Heart3D platforms are also described.
BioCardia, Inc. reports that President and CEO Peter Altman purchased 5,000 shares of common stock on July 29, 2026 at a weighted average price of $0.78 per share, executed in multiple trades between $0.77 and $0.80. Following this transaction, he directly holds 373,885 shares.
BioCardia, Inc. director and President & CEO Peter Altman purchased 500 shares of Common Stock on July 17, 2026 at $0.83 per share in an open-market transaction. After this trade, he directly owns 368,885 shares of BioCardia common stock.
The filing’s Rule 10b5-1 trading-plan checkbox was not selected.
BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of company common stock. He bought 2,800 shares at $0.88 on July 14, 2026 and 1,500 shares at $0.86 on July 15, 2026, bringing his direct holdings to 368,385 shares. The reported prices reflect weighted averages of multiple trades executed between $0.86 and $0.89 per share.
BioCardia, Inc. President and CEO Peter Altman reported a series of open‑market purchases of common stock. On July 8–10, 2026, he bought a total of 7,500 shares in three transactions, including 5,500 shares at $0.97, 1,000 shares at $0.90, and 1,000 shares at $0.94 per share. After these purchases, he directly owns 369,485 common shares. A footnote states that one transaction was executed in multiple trades between $0.92 and $1.05 per share and that the reported price is a weighted average, with full trade‑level details available upon request.
BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,400 shares of Common Stock at a weighted average price of $0.9645 per share. Following this transaction, he directly owns 361,985 shares. The trades were executed in multiple lots between $0.92 and $1.05 per share.
BioCardia, Inc. director Simon H. Stertzer received a grant of stock options as part of his compensation. He was awarded options to acquire 8,000 shares of BioCardia common stock at an exercise price of $1.20 per share, expiring on July 6, 2036. All of these options vest and become exercisable on the one-year anniversary of the grant date, as long as he continues as a service provider through that date. Following this grant, he holds stock options covering a total of 23,573 shares directly.
BioCardia director Marvin Slosman received a stock option grant for 8,000 shares of common stock on the reported date. The option has an exercise price of $1.20 per share and expires on July 6, 2036, bringing his directly held stock options to 20,000 shares. All 8,000 option shares vest and become exercisable on the one-year anniversary of the grant, provided he continues as a service provider through that date.
BioCardia, Inc. President and CEO Peter Altman reported routine equity compensation activity. On July 2, 2026, 54,606 shares of common stock were withheld by the company at $1.24 per share to cover income tax obligations on vested RSUs, and this did not represent a market sale by Altman. Following this tax-withholding disposition, he directly held 356,585 common shares. On July 6, 2026, he received a grant of stock options for 57,688 shares of common stock at a $1.20 exercise price, expiring on July 6, 2036, with vesting in 1/48th monthly installments beginning August 6, 2026, contingent on continued service, resulting in 147,903 options held after the grant.